Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION, STERILE
**Dosage and Administration** Instill 1 drop in the affected eye(s) once daily. **<Precautions>** Do not use more than once daily because more frequent administration may lessen the IOP-lowering effect.
OPHTHALMIC
Medical Information
**Indications** Reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
**Contraindications (This product is contraindicated in the following patients.)** Patients with a history of hypersensitivity to any of the ingredients of this product. Patients with combination with products containing omidenepag isopropyl.
S01EE05
tafluprost
Manufacturer Information
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Santen Pharmaceutical Co., Ltd. Shiga Plant
Active Ingredients
Documents
Package Inserts
PI_Taflotan_Singapore.pdf
Approved: October 7, 2021